

Rittler D, Baranyi M, Molnár E, Garay T, Jalsovszky I, Varga IK, Hegedűs L, Aigner C, **Tóvári J**, Tímár J, Hegedűs B. The Antitumor Effect of Lipophilic Bisphosphonate BPH1222 in Melanoma Models: The Role of the PI3K/Akt Pathway and the Small G Protein Rheb. *Int J Mol Sci.* 2019 Oct 3;20(19).

Baska F, Sipos A, Órfi Z, Nemes Z, Dobos J, Szántai-Kis C, Szabó E, Szénási G, Dézsi L, Hamar P, **Cserepes MT**, **Tóvári J**, Garamvölgyi R, Krekó M, Órfi L. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases. *Eur J Med Chem.* 2019 Oct 5;184:111710.

Randelović I, Schuster S, Kapuvári B, Fossati G, Steinkühler C, Mező G, **Tóvári J**. Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice. *Int J Mol Sci.* 2019 Sep 25;20(19). pii: E4763.

Vas V, Háhner T, Kudlik G, Ernszt D, Kvell K, Kuti D, Kovács KJ, **Tóvári J**, Trexler M, Merő BL, Szeder B, Koprivanacz K, Buday L. Analysis of Tks4 Knockout Mice Suggests a Role for Tks4 in Adipose Tissue Homeostasis in the Context of Beigeing. *Cells.* 2019 Aug 5;8(8). pii: E831

Madera-Sandoval RL, **Tóvári J**, Lövey J, **Randelović I**, Jiménez-Orozco A, Hernández-Chávez VG, Reyes-Maldonado E, Vega-López A. Combination of pentoxifylline and α -galactosylceramide with radiotherapy promotes necro-apoptosis and leukocyte infiltration and reduces the mitosis rate in murine melanoma. *Acta Histochem.* 2019 Aug;121(6):680-689.

Kiss K, Biri-Kovács B, Szabó R, **Randelović I**, Enyedi KN, Schlosser G, Orosz Á, Kapuvári B, **Tóvári J**, Mező G. Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems. *Eur J Med Chem.* 2019 Aug 15;176:105-116.

Kotlan B, Horvath S, Eles K, Plotar VK, Naszados G, Czirbesz K, Blank M, Farkas E, Toth L, **Tovari J**, Szekacs A, Shoenfeld Y, Godeny M, Kasler M, Liskay G. Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patients' Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor. *Front Immunol.* 2019 Apr 5;10:650.

Vas V, Kovács T, Körmendi S, Bródy A, Kudlik G, Szeder B, Mező D, Kállai D, Koprivanacz K, Merő BL, Dülk M, **Tóvári J**, Vajdovich P, Şenel ŞN, Özcan I, Helyes Z, Dobó-Nagy C, Buday L. Significance of the Tks4 scaffold protein in bone tissue homeostasis. *Sci Rep.* 2019 Apr 8;9(1):5781.

Laszlo V, Valko Z, Ozsvár J, Kovacs I, Garay T, Hoda MA, Klikovits T, Stockhammer P, Aigner C, Gröger M, Klepetko W, Berger W, Grusch M, **Tovari J**, Waizenegger IC, Dome B, Hegedus B. The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. Laszlo V, Valko Z, Ozsvár J, Kovacs I, Garay T, Hoda MA, Klikovits T, Stockhammer P, Gröger M, Klepetko W, Berger W, Grusch M, **Tovari J**, Waizenegger IC, Dome B, Hegedus B. *J Mol Med (Berl).* 2019 Feb;97(2):231-242.

2018

Csoboz B, Gombos I, Tatrai E, **Tovari J**, Kiss AL, Horvath I, Vigh L. Chemotherapy induced PRL3 expression promotes cancer growth via plasma membrane remodeling and specific alterations of caveolae-associated signaling. *Cell Commun Signal*. 2018 Aug 29;16(1):51.

Kenessey I, Kramer Z, István L, **Cserepes MT**, Garay T, Hegedűs B, Dobos J, Tímár J, **Tóvári J**. Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model. *Melanoma Res*. 2018 Dec;28(6):536-546.

Bánóczi Z, Keglevich A, Szabó I, Randelović I, Hegedűs Z, Regenbach FL, Keglevich P, Lengyel Z, Gorka-Kereskényi Á, Dubrovay Z, Háda V, Szigetvári Á, Szántay C Jr, Hazai L, **Tóvári J**, Hudecz F. The effect of conjugation on antitumor activity of vindoline derivatives with octaarginine, a cell-penetrating peptide. *J Pept Sci*. 2018 Oct;24(10):e3118

Bugyik E, Szabó V, Dezső K, Rókus A, Szücs A, Nagy P, **Tóvári J**, László V, Döme B, Paku S. Role of (myo)fibroblasts in the development of vascular and connective tissue structure of the C38 colorectal cancer in mice. *Cancer Commun (Lond)*. 2018 Jul 5;38(1):46.

Molnár E, Rittler D, Baranyi M, Grusch M, Berger W, Döme B, **Tóvári J**, Aigner C, Tímár J, Garay T, Hegedűs B. Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells. *BMC Cancer*. 2018 May 8;18(1):542.

Laszlo V, Valko Z, Kovacs I, Ozsvar J, Hoda MA, Klikovits T, Lakatos D, Czirok A, Garay T, Stiglbauer A, Helbich TH, Gröger M, **Tovari J**, Klepetko W, Pirker C, Grusch M, Berger W, Hilberg F, Hegedus B, Dome B. Nintedanib is active in malignant pleural mesothelioma cell models and inhibits angiogenesis and tumor growth *in vivo*. *Clin Cancer Res*. 2018 Aug 1;24(15):3729-3740.

2017.

Keller-Pinter A, Ughy B, Domoki M, Pettko-Szandtner A, Letoha T, **Tóvári J**, Timar J, Szilak L. The phosphomimetic mutation of syndecan-4 binds and inhibits Tiam1 modulating Rac1 activity in PDZ interaction-dependent manner. *PLoS One*. 2017 Nov 9;12(11):e0187094.

Füredi A, Szabényi K, Tóth S, **Cserepes M**, Hámori L, Nagy V, Karai E, Vajdovich P, Imre T, Szabó P, Szüts D, **Tóvári J**, Szakács G. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer. *J Control Release*. 2017 Sep 10;261: 287-296.

Tátrai E, Bartal A, Gacs A, Paku S, Kenessey I, Garay T, Hegedűs B, Molnár E, Cserepes MT, Hegedűs Z, Kucsma N, Szakács G, **Tóvári J**. Cell type-dependent HIF1 α -mediated

effects of hypoxia on proliferation, migration and metastatic potential of human tumor cells. *Oncotarget*. 2017 Jul 4;8(27): 44498-44510.

Donczo B, Szarka M, **Tóvári J**, Ostoros G, Csanky E, Guttman A. Molecular glycopathology by capillary electrophoresis: Analysis of the N-glycome of formalin-fixed paraffin-embedded mouse tissue samples. *Electrophoresis*. 2017 Jun;38(12): 1602-1608.

Füredi A, Tóth S, Szabó K, Pape VF, **Türk D**, Kucsma N, Cervenak L, **Tóvári J**, Szakács G. Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line-Specific Effects from P-Glycoprotein-Induced Toxicity. *Mol Cancer Ther*. 2017 Jan;16(1): 45-56.

2016.

Torok S, Rezeli M, Kelemen O, Vegvari A, Watanabe K, Sugihara Y, Tisza A, Marton T, Kovacs I, **Tóvári J**, Laszlo V, Helbich TH, Hegedus B, Klikovits T, Hoda MA, Klepetko W, Paku S, Marko-Varga G, Dome B.: Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors. *Theranostics*. 2017 Jan 1;7(2):400-412.

Gronewold A, Horn M, **Randelović I**, **Tóvári J**, Muñoz Vázquez S, Schomäcker K, Neundorf I.: Characterization of a Cell-Penetrating Peptide with Potential Anticancer Activity. *Chem Med Chem*. 2017 Jan 5;12(1):42-49.

Kenessey I, Kóí K, Horváth O, **Cserepes M**, Molnár D, Izsák V, Dobos J, Hegedűs B, **Tóvári J***, Tímár J*.: KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models. *Oncotarget*. 2016 Nov 29;7(48):79503-79514.

Kapuvári B, Hegedűs R, **Schulez A**, Manea M, **Tóvári J**, **Gacs A**, Vincze B, Mező G: Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice. *Invest New Drugs*. 2016 Aug;34(4):416-23.

Donczo B, Szigeti M, Ostoros G, Gacs A, **Tóvári J**, Guttman A. N-Glycosylation analysis of formalin fixed paraffin embedded samples by capillary electrophoresis. *Electrophoresis*. 2016 Sep;37(17-18):2292-6.

2015

Szabó K, Füredi A, Kolacsek O, Pergel E, Bősze Z, Bender B, Vajdovich P, **Tóvári J**, Homolya L, Szakács G, Héja L, Enyedi Á, Sarkadi B, Apáti Á, Orbán TI.: Generation of a Homozygous Transgenic Rat Strain Stably Expressing a Calcium Sensor Protein for Direct Examination of Calcium Signaling. *Sci Rep*. 2015 Aug 3;5:12645.

Szabó K, Füredi A, Kolacsek O, Csohány R, Prókai Á, Kis-Petik K, Szabó A, Bősze Z, Bender B, **Tóvári J**, Enyedi Á, Orbán TI, Apáti Á, Sarkadi B.: Visualization of Calcium Dynamics in Kidney Proximal Tubules. *J Am Soc Nephrol*. 2015 Nov;26(11):2731-40.

Lohinai Z, Hoda MA, Fabian K, Ostoros G, Raso E, Barbai T, Timar J, Kovalszky I, **Cserepes M**, Rozsas A, Laszlo V, Grusch M, Berger W, Klepetko W, Moldvay J, Dome B,

Hegedus B.: Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. *J Thorac Oncol*. 2015 May;10(5):738-46.

Garay T, Kenessey I, Molnár E, Juhász É, Réti A, László V, Rózsás A, Dobos J, Döme B, Berger W, Klepetko W, **Tóvári J**, Tímár J, Hegedűs B.: Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells. *PLoS One*. 2015 Feb 3;10(2):e0117021.

Torok S, Vegvari A, Rezeli M, Fehniger TE, **Tóvári J**, Paku S, Laszlo V, Hegedus B, Rozsas A, Dome B, Marko-Varga G.: Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study. *Br J Pharmacol*. 2015 Feb;172(4):1148-63.

Szabo V, Bugyik E, Dezso K, Ecker N, Nagy P, Timar J, **Tóvári J**, Laszlo V, Bridgeman VL, Wan E, Frentzas S, Vermeulen PB, Reynolds AR, Dome B, Paku S.: Mechanism of tumour vascularization in experimental lung metastases. *J Pathol*. 2015 Feb;235(3):384-96.

2014

Tóvári J, Futosi K, Bartal A, **Tátrai E, Gacs A**, Kenessey I, Paku S.: Boyden chamber-based method for characterizing the distribution of adhesions and cytoskeletal structure in HT1080 fibrosarcoma cells. *Cell Adh Migr*. 2014 Sep 3;8(5):509-16. doi: 10.4161/cam.28734.

Connell JJ, Sugihara Y, Török S, Döme B, **Tóvári J**, Fehniger TE, Marko-Varga G, Végvári A.: Localization of sunitinib in in vivo animal and in vitro experimental models by MALDI mass spectrometry imaging. *Anal Bioanal Chem*. 2014 Nov 26

Schelch K, Hoda MA, Klikovits T, Münzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, Filipits M, Pirker C, Heffeter P, Selzer E, **Tóvári J**, Torok S, Kenessey I, Holzmann K, Grasl-Kraupp B, Marian B, Klepetko W, Berger W, Hegedus B, Grusch M.: Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. *Am J Respir Crit Care Med*. 2014 Oct 1;190(7):763-72. doi: 10.1164/rccm.201404-0658OC.

Berta J, Hoda MA, Laszlo V, Rozsas A, Garay T, Torok S, Grusch M, Berger W, Paku S, Renyi-Vamos F, Masri B, **Tóvári J**, Groger M, Klepetko W, Hegedus B, Dome B.: Apelin promotes lymphangiogenesis and lymph node metastasis. *Oncotarget*. 2014 Jun 30;5(12):4426-37.

2013

Rózsás A, Berta J, Rojkó L, Horváth LZ, Keszthelyi M, Kenessey I, László V, Berger W, Grusch M, Hoda MA, Török S, Klepetko W, Rényi-Vámos F, Hegedűs B, Döme B, **Tóvári J**.: Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma. *PLoS One*. 2013 Oct 14;8(10):e77459. doi: 10.1371/journal.pone.0077459. eCollection 2013.

Nelhübel GA, Károly B, Szabó B, Lotz G, Kiss A, **Tóvári J**, Kenessey I.: The prognostic role of claudins in head and neck squamous cell carcinomas. *Pathol Oncol Res*. 2014 Jan;20(1):99-106. doi: 10.1007/s12253-013-9665-6. Epub 2013 Jul 12.

Lövey J, Nie D, **Tóvári J**, Kenessey I, Tímár J, Kandouz M, Honn KV.: Radiosensitivity of human prostate cancer cells can be modulated by inhibition of 12-lipoxygenase. *Cancer Lett.* 2013 Jul 28;335(2):495-501. doi: 10.1016/j.canlet.2013.03.012. Epub 2013 Mar 21.

Dobos J, Mohos A, **Tóvári J**, Rásó E, Lőrincz T, Zádori G, Tímár J, Ladányi A.: Sex-dependent liver colonization of human melanoma in SCID mice--role of host defense mechanisms. *Clin Exp Metastasis.* 2013 Apr;30(4):497-506. doi: 10.1007/s10585-012-9554-5. Epub 2012 Dec 1.

2012

Bugyik E, Dezso K, Reiniger L, László V, **Tóvári J**, Tímár J, Nagy P, Klepetko W, Döme B, Paku S.: Lack of angiogenesis in experimental brain metastases. *J Neuropathol Exp Neurol.* 2011 Nov;70(11):979-91. doi: 10.1097/NEN.0b013e318233afd7.

Flachner B, Lőrincz Z, Carotti A, Nicolotti O, Kuchipudi P, Remez N, Sanz F, **Tóvári J**, Szabó MJ, Bertók B, Cseh S, Mestres J, Dormán G.: A chemocentric approach to the identification of cancer targets. *PLoS One.* 2012;7(4):e35582. doi: 10.1371/journal.pone.0035582. Epub 2012 Apr 25

Manea M, **Tóvári J**, **Tejeda M**, **Schulcz A**, Kapuvári B, Vinczec B, Mezo G: In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice. *ANTI-CANCER DRUGS* 23:(1) pp. 90-97. (2012)

Manea M, Leurs U, Orbán E, Schreier VN, Pethő L, Schlage P, Schulcz Á, Kapuvári B, **Tóvári J**, Halmos G, Mező G: Anticancer drug delivery systems containing GnRH-III as a targeting moiety. *JOURNAL OF PEPTIDE SCIENCE* 18:(S1) p. 46. 1 p. (2012)

Kenessey I, Bánki B, Márk A, Varga N, **Tóvári J**, Ladányi A, Rásó E, Tímár J: Revisiting CB1 Receptor as Drug Target in Human Melanoma. *PATHOLOGY & ONCOLOGY RESEARCH* 18:(4) pp. 857-866. (2012)

Hegedüs R, Manea M, Orbán E, Szabó I, Sipos É, Halmos G, Kapuvári B, **Schulcz Á**, **Tóvári J**, Mező G: Short-chain fatty acid acylated daunorubicin -GnRH-III bioconjugates with enhanced cellular uptake, in vitro and in vivo antitumor activity. *JOURNAL OF PEPTIDE SCIENCE* 18:(S1) p. 155. 1 p. (2012)

Flachner B, Lőrincz Z, Carotti A, Nicolotti O, Kuchipudi P, Remez N, Sanz F, **Tóvári J**, Szabó MJ, Bertók B, Cseh S, Mestres J, Dormán G: An Efficient Chemocentric Approach to the Identification of Protein Signatures Relevant to Cancer. *PLOS ONE* 7:(4) p. e35582. (2012)

2011

Szabó B, Nelhübel GA, Kárpáti A, Kenessey I, Jóri B, Székely Cs, Peták I, Lotz G, Hegedüs Z, Hegedüs B, Füle T, Döme B, Tímár J, **Tóvári J**: Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. *ORAL ONCOLOGY-EUROPEAN JOURNAL OF CANCER PART B* 47:(6) pp. 487-496. (2011)

Paku S, Dezso K, Bugyik E, **Tóvári J**, Timar J, Nagy P, Laszlo V, Klepetko W, Dome B: A New Mechanism for Pillar Formation during Tumor-Induced Intussusceptive Angiogenesis:

Inverse Sprouting. AMERICAN JOURNAL OF PATHOLOGY 179:(3) pp. 1573-1585. (2011)

Manea M, Leurs U, Orban E, Baranyai Z, Ohlschlager P, Marquardt A, **Schulcz A, Tejeda M, Kapuvári B, Tóvári J**, Mezo G: Enhanced Enzymatic Stability and Antitumor Activity of Daunorubicin-GnRH-III Bioconjugates Modified in Position 4. BIOCONJUGATE CHEMISTRY 22:(7) pp. 1320-1329. (2011)

9. Bugyik E, Dezso K, Reiniger L, Laszlo V, **Tóvári J**, Timar J, Nagy P, Klepetko W, Dome B, Paku S: Lack of Angiogenesis in Experimental Brain Metastases. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY 70:(11) pp. 979-991. (2011)

2010

Kenessey I, Keszthelyi M, Kramer ZF, Berta J, Adam A, Dobos J, Mildner M, Flachner B, Cseh S, Barna G, Szokol B, Orfi L, Keri G, Dome B, Klepetko W, Timar JZ, **Tóvári J**: Inhibition of c-Met with the Specific Small Molecule Tyrosine Kinase Inhibitor SU11274 Decreases Growth and Metastasis Formation of Experimental Human Melanoma. CURRENT CANCER DRUG TARGETS 10:(3) pp. 332-342. (2010)

11. Kapuvári B, Vincze B, Manea M, **Tejeda M, Schulcz A, Tóvári J, Gaál D**, Orbán E, Szabó I, Mező G: Development of drug delivery systems for targeted cancer chemotherapy based on GnRH antagonist and agonist peptides. JOURNAL OF PEPTIDE SCIENCE 16: p. 186. (2010)

Berta J, Kenessey I, Dobos J, **Tóvári J**, Klepetko W, Ankersmit HJ, Hegedus B, Rényi-Vámos F, Varga J, Lorincz Zs, Paku S, Ostoros Gy, Rozsas A, Timar J, Dome B: Apelin expression in human non-small cell lung cancer: Role in angiogenesis and prognosis. JOURNAL OF THORACIC ONCOLOGY 5:(8) pp. 1120-1129. (2010)

2009

Keszthelyi M, Dome B, **Tóvári J**, Timar J: Clinical significance of vegfr-3 positive circulating lymphatic/vascular endothelial progenitor cells in small cell lung cancer. LUNG CANCER 64: pp. S64-S65. (2009)

Kenessey I, Simon E, Futosi K, Bereczky B, Kiss A, Erdődi F, Gallagher JT, Tímár J, **Tóvári J**: Antimigratory and antimetastatic effect of heparin-derived 4-18 unit oligosaccharides in a preclinical human melanoma metastasis model. THROMBOSIS AND HAEMOSTASIS 102: pp. 1265-1273. (2009)

Döme P, Teleki Z, Rihmer Z, Peter L, Dobos J, Kenessey I, **Tóvári J**, Tímár J, Paku S, Kovács G, Döme B: Circulating endothelial progenitor cells and depression: a possible novel link between heart and soul. MOLECULAR PSYCHIATRY 14: pp. 523-531. (2009)

Döme B, Tímár J, Ladányi A, Paku S, Rényi-Vámos F, Klepetko W, Láng Gy, Döme P, Bogos K, **Tóvári J**: Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic haematopoietic cells in cancer: from biology to therapy. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 69:(2) pp. 108-124. (2009)

Dezső K, Bugyik E, Papp V, László V, Döme B, **Tóvári J**, Tímár J, Nagy P, Paku S: Development of arterial blood supply in experimental liver metastases. *AMERICAN JOURNAL OF PATHOLOGY* 175:(2) pp. 835-843. (2009)

Bogos K, Renyi-Vamos F, Dobos J, **Tóvári J**, Ostoros G, Dome B: Quantification of Circulating Vascular Endothelial Growth Factor Receptor-3-Positive Lymphatic/Vascular Endothelial Progenitor Cells Response. *CLINICAL CANCER RESEARCH* 15:(21) pp. 6740-6742. (2009)

Bogos K, Rényi-Vámos F, Dobos J, Kenessey I, **Tóvári J**, Tímár J, Strausz J, Ostoros Gy, Klepetko W, Ankersmit HJ, Láng Gy, Hoda MA, Nierlich P, Döme B: High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer. *CLINICAL CANCER RESEARCH* 15:(5) pp. 1741-1746. (2009)

Ildikó Szabó, Marilena Manea, Erika Orbán, Antal Csámpai, Szilvia Bősze, Rita Szabó, **Miguel Tejada**, **Dezső Gaál**, Bence Kapuvári, Michael Przybylski, Ferenc Hudecz, and Gábor Mező: Development of an Oxime Bond Containing Daunorubicin-Gonadotropin-Releasing Hormone-III Conjugate as a Potential Anticancer Drug. *BIOCONJUGATE CHEM.* 20, 656–665, (2009)

2008

Tóvári J: Exogenous erythropoietin modifies tumor-induced neoangiogenesis in human tumor models. *ANTICANCER RESEARCH* 28:(5C) pp. 3521-3522. (2008)

Tóvári J, Pirker R, Timar J, Ostoros G, Kovacs G, Dome B: Erythropoietin in cancer: An update. *CURRENT MOLECULAR MEDICINE* 8:(6) pp. 481-491. (2008)

Lövey J, Bereczky B, Gilly R, Kenessey I, Rásó E, Simon E, Dobos J, Vágó A, Kásler M, Döme B, Tímár J, **Tóvári J**: Recombinant human erythropoietin-alpha improves the efficacy of radiotherapy of a human tumor xenograft, affecting tumor cells and microvessels. *STRAHLENTHERAPIE UND ONKOLOGIE* 184:(1) pp. 1-7. (2008)

Döme B, Dobos J, **Tóvári J**, Paku S, Kovács G, Ostoros G, Tímár J: Circulating bone marrow-derived endothelial progenitor cells: characterization, mobilization, and therapeutic considerations in malignant disease. *CYTOMETRY PART A* 73A:(3) pp. 186-193. (2008)

Bogos K, Renyi-Vamos F, Kovacs G, **Tóvári J**, Dome B: Role of retinoic receptors in lung carcinogenesis. *JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH* 27: Paper 18. 7 p. (2008)

Amir E, Hughes S, Blackhall F, Thatcher N, Ostoros G, Tímár J, **Tóvári J**, Kovács G, Döme B: Targeting blood vessels for the treatment of non-small cell lung cancer. *CURRENT CANCER DRUG TARGETS* 8:(5) pp. 392-403. (2008)

Tejada M, **Gaal D**, Hullan L: Continuous Administration of the Somatostatin Structural Derivative vertical bar TT-232 vertical bar by Subcutaneously Implanted Osmotic Pump Improves the Efficacy and Potency of Antitumor Therapy in Different Mouse and Human

Tumor Models. ANTICANCER RESEARCH Volume: 28 Issue: 5A Pages: 2769-2774 (2008)

Manea, Marilena, Szabo, Ildiko, Orban, Erika, **Gaal Dezso**, Csampai Antal, Bosze Szilvia, Mezo Gabor: JOURNAL OF PEPTIDE SCIENCE Volume: 14 Issue: 8 Pages: 116-116 (2008)

Szabo I, Bosze S, Orban E, **Gaál D**: In vitro and in vivo antitumor effect of symmetric GNRH-111 dimer derivatives: JOURNAL OF PEPTIDE SCIENCE Volume: 14 Issue: 8 Pages: 117-117 (2008).

2007

Tóvári J, Dobos J, Kenessey I, Ostoros G, Kovacs G, Timar J, Dome B: Level of circulating endothelial progenitor cells is a potential surrogate marker in human non-small cell lung cancer. EJC SUPPLEMENTS 5:(4) p. 385. (2007)

Lövey J, Kenessey I, Rásó E, Dobos J, Vágó Á, Kásler M, Futosi K, Döme B, Timár J, **Tóvári J**: A rekombináns human erythropoietin-alpha fokozza a human laphámrák sugárérzékenységét preklinikai modellben. MAGYAR ONKOLÓGIA 51:(1) pp. 53-61. (2007)

Kiss J, Kunstar A, Fajka-Boja R, Dudics V, **Tóvári J**, Legradi A, Monostori E, Uher F: Galectin-1 inhibits hematopoietic stem and progenitor cell mobilization. BLOOD REVIEWS 21: p. S88. (2007)

Kiss J, Kunstar A, Fajka-Boja R, Dudics V, **Tóvári J**, Legradi A, Monostori E, Uher F: A novel anti-inflammatory function of human galectin-1: Inhibition of hematopoietic progenitor cell mobilization. EXPERIMENTAL HEMATOLOGY 35:(2) pp. 305-313. (2007)

Horváth A, Sepródi J, Vántus T, Bökönyi GY, Tanai H, **Tóvári J**, Kenessey I, Kéri G: Influence of angiogenesis by new synthetic peptides and peptidomimetics. TISSUE ENGINEERING 13:(7) p. 1714. (2007)

Dome B, Hendrix MJC, Paku S, **Tóvári J**, Timar J: Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. AMERICAN JOURNAL OF PATHOLOGY 170:(1) pp. 1-15. (2007)

Deli T, Varga N, Adam A, Kenessey I, Raso E, Puskas LG, **Tóvári J**, Fodor J, Feher M, Szigeti G P, Csernoch L, Timar J: Functional genomics of calcium channels in human melanoma cells. INTERNATIONAL JOURNAL OF CANCER 121:(1) pp. 55-65. (2007)

Tejeda M, **Gaal D**, Hullan L: Antitumor activity of the somatostatin structural derivative (TT-232), against mouse and human melanoma tumor models. ANTICANCER RESEARCH Volume: 27 Issue: 6B Pages: 4015-4019 (2007)

2006

Timar J, Paku S, **Tóvári J**, Dome B: Az antivaszkuláris terápia elvi alapjai. MAGYAR ONKOLÓGIA 50:(2) pp. 141-151. (2006)

Horváth A, Seprődi J, Vántus T, Idei M, Bökönyi Gy, **Tóvári J**, Kenessey I, Kéri Gy: Effect of new synthetic peptides and peptidomimetics on angiogenesis. JOURNAL OF PEPTIDE SCIENCE 12:(Suppl) pp. 249-250. (2006)

Dome B, Timar J, Dobos J, Meszaros L, Raso E, Paku S, Kenessey I, Ostoros G, Magyar M, Ladanyi A, Bogos K, **Tóvári J**: Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. CANCER RESEARCH 66:(14) pp. 7341-7347. (2006)

Tejeda M, Gaal D, Hullan L: Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models. ANTICANCER RESEARCH Volume: 26 Issue: 5A Pages: 3477-3483 (2006)

Tejeda M, Gaal D, Hullan L:

A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models. ANTICANCER RESEARCH Volume: 26 Issue: 4B Pages: 3011-3015 (2006)

2005

Tóvári J, Gilly R, Raso E, Paku S, Bereczky B, Varga N, Vago A, Timar J: Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models. CANCER RESEARCH 65:(16) pp. 7186-7193. (2005)

Tímár J, **Tóvári J**, Rásó E, Mészáros L, Bereczky B, Lapis K: Platelet-mimicry of cancer cells: epiphenomenon with clinical significance. ONCOLOGY 69:(3) pp. 185-201. (2005)

Renyi-Vamos F, **Tóvári J**, Fillinger J, Timar J, Paku S, Kenessey I, Ostoros G, Agocs L, Soltesz I, Dome B: Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. CLINICAL CANCER RESEARCH 11:(20) pp. 7344-7353. (2005)

Rásó E, **Tóvári J**, Ladányi A, Varga N, Tímár J: Ligand-mimetic anti-alphaIIbeta3 antibody PAC-1 inhibits tyrosine signaling; proliferation and lung colonization of melanoma cells. PATHOLOGY & ONCOLOGY RESEARCH 11:(4) pp. 218-223. (2005)

Pintér F, Moldvay J, **Tóvári J**, Pápay J, Almási A, Kánya M, Tamási A, Tímár J, Schwab R, Kéri Gy, Kopper L, Peták I: Az EGFR (Epidermális Növekedési Faktor Receptor) mutációinak kimutatása rendkívül kis szövetminták esetén. MAGYAR ONKOLOGIA 49:(Suppl.1) p. 70. (2005)

Drén NCS, Számadó CS, Dobos-Kovács M, **Tóvári J**, Levy A, Kumar PM, Parcells MS: Isolation of a highly oncogenic Marek's disease virus from layer parent flocks from Hungary. In: Nair V (szerk.). Recent advances in Marek's disease research. Proceedings of the 7th International Symposium 2004. Oxford: ST CATHRINE'S COLLEGE, pp. 166-172.

Dome B, Timar J, Ostoros G, Meszaros L, Dobos J, Raso E, Renyi-Vamos F, Bogos J, Agocs L, **Tóvári J**: The role of circulating endothelial progenitor cells in non-small cell lung cancer. LUNG CANCER 49:(2) pp. S368-S369. (2005)

Bereczky B, Gilly R, Rásó E, Vágó Á, Tímár J, **Tóvári J**: Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest. *CLINICAL & EXPERIMENTAL METASTASIS* 22:(1) pp. 69-76. (2005)

Molnar J, Thornton BS, Molnar A, **Gaal D**: Thermodynamic aspects of cancer: Possible role of negative entropy in tumor growth, its relation to kinetic and genetic resistance. *LETTERS IN DRUG DESIGN & DISCOVERY* Vol: 2 Issue: 6 Pages: 429-438 (2005)

Molnár J., Thornton B.S., Molnár A., **Gaal D.**, Lio L. and Bergmann-Leitner E.S: Thermodynamic aspects of cancer: Possible role of negative entropy in tumor growth, its relation to kinetic and genetic resistance. *LETTERS IN DRUG DESIGN AND DISCOVERY*, 2: 429-439, (2005)

Tejeda M, Gaal D, Csuka O: Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models. *ANTICANCER RESEARCH* Volume: 25 Issue: 1A Pages: 325-330 (2005)

2004

Tóvári J, Paku S, Raso E, Timar F, Puskas L, Timar J: Mechanism of cell movement in metastatic human tumor cells. *ANTICANCER RESEARCH* 24:(5D) pp. 3656-3657. (2004)

Tóvári J, Berenczky B, Gilly R, Skopál J, Vágó Á, Tímár J: Heparinkezelés hatása a melanoma áttétképzésére preklinikai modellben: Heparinkezelés hatása a melanoma áttétképzésére preklinikai modellben. *MAGYAR ONKOLÓGIA* 48:(3) pp. 235-241. (2004)

Timar J, Gillyen R, Lovey J, Bereczky B, **Tóvári J**: Effect of rH-erythropoietin-a on tumor vasculature and sensitivity to irradiation in epidermoid cancer xenograft. *JOURNAL OF CLINICAL ONCOLOGY* 22:(14S) p. 512S. (2004)

Hudecz F, Remenyi J, Hegedus T, **Gaal D**: Peptide targeting of daunomycin into sensitive and multidrug resistant tumors. *Peptide Revolution: Genomics, Proteomics & Therapeutics* Pages: 815-817 Published: 2004

Molnar J, Mucsi I, Nacsá J, **Gaal D**: New silicon compounds as resistance modifiers against multidrug-resistant cancer cells. *ANTICANCER RESEARCH* Volume: 24 Issue: 2B Pages: 865-871 (2004)

Mezo G, Kalaszi A, Remenyi J, **Gaal D**: Synthesis, conformation, and immunoreactivity of new carrier molecules based on repeated tuftsin-like sequence. *BIOPOLYMERS* Volume: 73 Issue: 6 Pages: 645-656 (2004)

2003

Tejeda M, Gaal D, Barna K: The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts. *ANTICANCER RESEARCH* Volume: 23 Issue: 5A Pages: 4061-4066(2003)

Hudecz F, Remenyi J, Szabo B, **Gaal D**: Peptide targeting of daunomycin into sensitive and multidrug resistant tumors. *BIOPOLYMERS* Volume: 71 Issue: 3 Pages: 299-299 (2003)

Hudecz F, Remenyi J, Szabo R, **Gaal D**: Drug targeting by macromolecules without recognition unit? JOURNAL OF MOLECULAR RECOGNITION Vol: 16 Issue: 5 Pages: 288-298 (2003)

Tejeda M, Gaal D, Csuka O: The antitumor effect of the somatostatin analogue TT-232 depends on the treatment regimen. CANCER DETECTION AND PREVENTION Vol: 27 Issue: 2 Pages: 155-162 (2003)

Hudecz F, Remenyi J, Szabo B, **Gaal D**: Peptide targeting of daunomycin into sensitive and multidrug resistant tumors. BIOPOLYMERS Volume: 71 Issue: 3 Pages: 410-410 Meeting Abstract: P500 (2003)

Paku S, **Tóvári J**, Lorincz Z, Timar F, Dome B, Kopper L, Raz A, Timar J: Adhesion dynamics and cytoskeletal structure of gliding human fibrosarcoma cells: a hypothetical model of cell migration. EXPERIMENTAL CELL RESEARCH 290:(2) pp. 246-253. (2003)

2002

Radak Z, **Gaal D**, Taylor AW: Attenuation of the development of murine solid leukemia tumor by physical exercise. ANTIOXIDANTS & REDOX SIGNALING Volume: 4 Issue: 1 Pages: 213-219 (2002)

2001

Radak Z, Taylor AW, Sasvari M, **Gaal D**: Telomerase activity is not altered by regular strenuous exercise in skeletal muscle or by sarcoma in liver of rats. REDOX REPORT Volume: 6 Issue: 2 Pages: 99-103 (2001)

Palyi I, Vincze B, Mezo I, **Gaal D**: GnRH analog conjugates with high anticancer selectivity DRUGS OF THE FUTURE Volume: 26 Issue: 1 Pages: 51-59 (2001)

Rásó E, **Tóvári J**, Tóth K, Paku S, Trikha M, Honn KV, Tímár J: Ectopic alpha IIb beta 3 integrin signaling involves 12-lipoxygenase- and PKC-mediated serine phosphorylation events in melanoma cells. THROMBOSIS AND HAEMOSTASIS 85:(6) pp. 1037-1042. (2001)

2000

Tejeda M, Gaal D, Schwab RE: Influence of various administration routes on the antitumor efficacy of TT-232, a novel somatostatin analog. ANTICANCER RESEARCH Volume: 20 Issue: 2A Pages: 1023-1027 (2000)

Mezo G, Remenyi J, Kajtar J, **Gaal D**: Synthesis and conformational studies of poly(L-lysine) based branched polypeptides with Ser and Glu/Leu in the side chains. JOURNAL OF CONTROLLED RELEASE Volume: 63 Issue: 1-2 , 81-95 (2000)

1999

Timar J, Toth S, **Tóvári J**, Paku S, Raz A: Autocrine motility factor (neuroleukin, phosphohexose isomerase) induces cell movement through 12-lipoxygenase-dependent tyrosine phosphorylation and serine dephosphorylation events. CLINICAL & EXPERIMENTAL METASTASIS 17:(10) pp. 809-816. (1999)

Dome B, Somlai B, Tamasy A, Peter L, **Tóvári J**, Horvath A, Timar J. A cutan melanoma prognostic and invasive marker expression. Metastatic associated genes (nm23, CD44v3, MMP2). *ORVOSI HETILAP* 140:(5) pp. 235-240. (1999)

Hudecz F, Pimm MV, Rajnavolgyi E, **Gaal D**: Carrier design: New generation of polycationic branched polypeptides containing OH groups with prolonged blood survival and diminished in vitro cytotoxicity. *BIOCONJUGATE CHEMISTRY* Volume: 10 Issue: 5 Pages: 781-790, (1999)

Palyi I, Vincze B, Lovas S, **Gaal D**: Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA* Volume: 96 Issue: 5 Pages: 2361-2366, (1999)

1998

Tóvári J, Szende B, Bocsi J, Falaschi A, Simoncsits A, Pongor S, Erchegeyi J, Stetak A, Keri G: A somatostatin analogue induces translocation of Ku 86 autoantigen from the cytosol to the nucleus in colon tumour cells. *CELLULAR SIGNALLING* 10:(4) pp. 277-282. (1998)

Repassy G, **Tóvári J**, Horvath-Foster C, Tamasi A, Timar J, Tamas L, Ribari O: Expression of invasion markers and metastasis genes in laryngeal and hypopharyngeal tumors. *BRITISH JOURNAL OF CANCER* 77:(Suppl. 1) p. 4. (1998)

Kovalszky I, Dudas J, Olahnagyi J, Pogany G, **Tóvári J**, Timar J, Kopper L, Jeney A, Iozzo RV: Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor. *MOLECULAR AND CELLULAR BIOCHEMISTRY* 183:(1-2) pp. 11-23. (1998)

Csuka O, Olasz J, Doleschall Z, **Gaal D**: Molecular mechanism of the Taxol sensitivity of tumor cells. *ANNALS OF ONCOLOGY* Vol: 9 Pages: 103-103 Suppl: Suppl. 2 (1998)

Gaal D, **Tejeda M**, **Barna SK**: Influence of various administration routes on the antitumor activity and apoptosis induction of TT-232, as a novel somatostatin analog. *ANNALS OF ONCOLOGY* Vol: 9 Pages: 106-106 Sup.Suppl. 2 (1998)

Gaal D, Hudecz F: Low toxicity and high antitumor activity of daunomycin by conjugation to an immunopotential amphoteric branched polypeptide. *EUROPEAN JOURNAL OF CANCER* Vol: 34 Issue: 1 Pages: 155-161, (1998)

1997

Tóvári J, Paku S, Rásó E, Pogány G, Kovalszky I, Ladányi A, Lapis K, Timár J: Role of sinusoidal heparan sulphate proteoglycan in liver metastasis formation. *INTERNATIONAL JOURNAL OF CANCER* 71: pp. 825-831. (1997)

Timár J, **Tóvári J**, Szekeres K, Kagawa D, Honn KV: Key determinants of the invasion mechanism of melanoma. Role for a new signaling pathway. *ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY* 407: pp. 303-310. (1997)

Szebeni J, Barna K, Uher F, **Gaal D**: Comparison of the lymphoid toxicities of mitobronitol and busulphan in mice: reduced B cell toxicity and improved thymic recovery as possible contributors to the reduced risk for complications following BMT with mitobronitol preconditioning. LEUKEMIA Volume: 11 Issue: 10 Pages: 1769-1774 (1997)

1996

Tóvári J, Bocsi J, Ladányi A, Lapis K, Tímár J: The antitumor effect of tiazofurin (TR) consists of anti-proliferative and anti-invasive elements. ANTICANCER RESEARCH 16: pp. 3307-3312. (1996)

Tímár J, **Tóvári J**, Pogány G, Ladányi A, Paku S, Rásó E, Bocsi J, Jeney A, Lapis K: The antimetabolite tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells. EUROPEAN JOURNAL OF CANCER 32A:(1) pp. 152-159. (1996)

Tímár J, Trikha M, Szekeres K, Bazaz R, **Tóvári J**, Silletti S, Raz A, Honn KV: Autocrine motility factor signals integrin-mediated metastatic melanoma cell adhesion and invasion. CANCER RESEARCH 56:(8) pp. 1902-1908. (1996)

Lapis K, Rásó E, **Tóvári I**, Bocsi J, Oláh E, Járai Köte Zs, Bartha I, Jeney A, Tímár J: Antiproliferative and antimetastatic effect of tiazofurin. CLINICAL & EXPERIMENTAL METASTASIS 14: p. 86. (1996)

Lapis K, Bocsi J, **Tóvári J**, Bartha I, Tímár J, Rásó E: Antiinvasive effects of tiazofurin on liver-metastatic human colon carcinoma xenograft. ANTICANCER RESEARCH 16:(6A) pp. 3323-3332. (1996)

Keri G, Erchegeyi J, Horvath A, **Gaal D**: A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA Volume: 93 Issue: 22 Pages: 12513-12518, (1996)

Vincze B, Palyi I, **Gaal D**: In vivo studies of the new gonadotropin-releasing hormone antagonist-copolymer conjugates having antitumor activity. CANCER DETECTION AND PREVENTION Vol: 20 Issue: 2 Pages: 153-159 (1996)

1995

Tímár J, Diczhazi C, Bartha I, Pogány G, Paku S, Rásó E, **Tóvári J**, Ladányi A, Lapis K, Kopper L, Jeney A: Modulation of heparan-sulphate/chondroitin-sulphate ratio by glycosaminoglycan biosynthesis inhibitors affects liver metastatic potential of tumor cells. INTERNATIONAL JOURNAL OF CANCER 62:(6) pp. 755-761. (1995)

Tímár J, Bazaz R, Kimler V, Haddad M, Tang DG, Robertson D, **Tóvári J**, Taylor JD, Honn KV: Immunomorphological characterization and effects of 12-(S)-HETE on a dynamic intracellular pool of the α IIb3-integrin in melanoma cells. JOURNAL OF CELL SCIENCE 108:(Part 6) pp. 2175-2186. (1995)

Lapis K, Rásó E, Bocsi J, **Tóvári I**, Bartha J, Oláh E, Járai Köte Zs, Tímár J: Antiinvasive and Antimetastatic Effect of Tiazofurin on Human Tumors. ANTICANCER RESEARCH 15:(5A) p. 1809. (1995)

Ladányi A, Tímár J, Bocsi J, **Tóvári J**, Lapis K: Sex-dependent live metastasis of human melanoma lines in SCID mice. MELANOMA RESEARCH 5:(2) pp. 83-86. (1995)

Gaal D, Hendriks HR: Effect of OM-163, a new biological response modifier on the immunosuppression caused by cytostatics and ionizing radiation. EUROPEAN JOURNAL OF CANCER Volume: 31A Pages: 593-593, (1995)

Pimm M.V., Perkins A.C., Gribben S.J., Mező G., **Gaal D.**, Hudecz F: Gamma scintigraphy of ¹¹¹In labelled branched chain polypeptides (BCP) with a poly-(L-Lysine) backbone in mice with mammary carcinoma: Effect of change on biodistribution and tumour imaging potential. ANNALS OF NUCLEAR MEDICINE 9 (4): 247-252, (1995)

1993

Paku S, **Tóvári J**, Kovalszky I, Rásó E, Tímár J, Lapis K: Anti-Sinusoidal HSPG Antibody Inhibits Liver Metastasis Formation. ANTICANCER RESEARCH 13: p. 2598. (1993)

Institoris E, Tretter L, **Gaal D**: Severe depletion of cellular thiols and glutathione-related enzymes of a carmustine-resistant 11210 strain associates with collateral sensitivity to cyclophosphamide. CANCER CHEMOTHERAPY AND PHARMACOLOGY Vol: 33 Issue: 1 Pages: 85-88 (1993)

1992

Hudecz F, **Gaal D**, Kurucz I: Carrier design - cytotoxicity and immunogenicity of synthetic branched polypeptides with poly(l-lysine) backbone. JOURNAL OF CONTROLLED RELEASE Volume: 19 Issue: 1-3 Pages: 231-243 (1992)

1986

Gaal D, Hudecz F, Kovacs AI: Immunomodulatory effect of synthetic branched polypeptides .2. JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS Volume: 5 Issue: 2 Pages: 148-159, (1986)

Gero E, **Gaal D**: Inhibitory and stimulatory effects of dianhydrogalactitol, an alkylating cytostatic agent on the humoral immune-response. ONCOLOGY Volume: 43 Issue: 2 Pages: 98-102, (1986)

Csuka O., **Gaal D.**, Sugár J: Effect of immunomodulation on the experimental metastasis formation. LE METASTASI, MONDUZZI EDITORE, Vol.1. pp.21-29. (1986)

1986

Gaal D, Hudecz F, Szekerke M: The influence of endotoxins and polypeptide immunomodulators on the immunosuppression and toxic effect induced by chemotherapy and radiotherapy. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY Volume: 21 Issue: 11 Pages: 1384-1384, (1985)

1984

Gaal D, Kremmer T, Balint Z: Effects of bacterial-endotoxins and their detoxified derivatives on serum and liver lipids in mice. TOXICOLOGY AND APPLIED PHARMACOLOGY Volume: 75 Issue: 3 Pages: 437-443, (1984).

Gaal D, Hudecz F, Szekerke M: Immunomodulatory effect of synthetic branched polypeptides .1. JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS Volume: 3 Issue: 2 Pages: 174-184 (1984)

1982

Gaal D, Kremmer T, Balint Z: Alterations in lipid-metabolism of mice treated with endotoxic lipopolysaccharides and detoxified preparations. ACTA BIOCHIMICA ET BIOPHYSICA HUNGARICA Volume: 17 Issue: 1-2 Pages: 52-52, (1982)

Gaal D., Hudecz F., Szekerke M: Immunomodulatory effect of synthetic branched polypeptides. IMMUNOCHEMISTRY , 96, 567-572, (1982)

1979

Gaal D, Nowotny A: Immune enhancement by tumor-therapeutic drugs and endotoxins. CANCER IMMUNOLOGY IMMUNOTHERAPY Vol: 6 Issue: 1 Pages: 9-15 (1979)

1978

Blazsek I, **Gaal D**: Endogenous thymic factors regulating cell-proliferation and analysis of their mechanism of action. CELL AND TISSUE KINETICS Volume: 11 Issue: 3 Pages: 265-277, (1978)

1977

Balazs A, Klupp A, Zsila G, **Gaal D**: Modulative effect of endogenous granuloid inhibitors on cell-proliferation. MECHANISMS OF AGEING AND DEVELOPMENT Volume: 6 Issue: 3 Pages: 207-218 (1977)

1976

Blazsek I, Balazs A, **Gaal D**: Multifactorial system controlling myeloid cell-differentiation and division. MECHANISMS OF AGEING AND DEVELOPMENT Volume: 5 Issue: 1 Pages: 57-65 (1976)

1975

Gaal D, Holczinger L.: Effect of detergents and sucrose derivatives on modified protein determination of lowry. ACTA BIOCHIMICA ET BIOPHYSICA HUNGARICA Volume: 10 Issue: 3 Pages: 201-206, (1975)